Table 6.
GO categories of SUMO targeting genes with no expression changes during KSHV reactivation
| SUMO-2/3 12 h | SUMO-2/3 enriched at 12 hr | |||||||
|---|---|---|---|---|---|---|---|---|
| All genes | Gene expression no change | Gene expression no change | ||||||
| Pathway category | Genes in category | Genes identified | p-value | Genes identified | p-value | Genes identified | p-value | |
| Pathogen-influenced signaling | Virus entry via endocytic pathways | 99 | 31 | 1.41E-03 | 28 | 3.24E-03 | 20 | 5.13E-03 |
| Cellular immune response | Antigen Presentation pathway | 40 | 14 | 1.26E-02 | 12 | 3.63E-02 | 9 | 3.24E-02 |
| CD40 signaling | 70 | 23 | 2.82E-03 | 21 | 4.79E-03 | 14 | 1.91E-02 | |
| HMGB1 signaling | 99 | 25 | 9.33E-02 | 24 | 6.46E-02 | 16 | 1.03E-01 | |
| IL-10 signaling | 78 | 19 | 9.55E-02 | 16 | 2.07E-01 | 11 | 2.10E-01 | |
| IL-15 signaling | 67 | 20 | 1.86E-02 | 19 | 1.55E-02 | 16 | 2.34E-03 | |
| IL-3 signaling | 74 | 23 | 1.41E-02 | 22 | 1.02E-02 | 14 | 4.90E-02 | |
| IL-8 signaling | 205 | 48 | 4.68E-02 | 44 | 6.92E-02 | 27 | 2.14E-01 | |
| NF-κB activation by viruses | 82 | 23 | 2.00E-02 | 21 | 3.16E-02 | 15 | 3.39E-02 | |
| p38 MAPK signaling | 117 | 26 | 3.80E-01 | 24 | 3.88E-01 | 16 | 3.79E-01 | |
| Toll-like receptor signaling | 62 | 17 | 5.75E-02 | 15 | 9.55E-02 | 11 | 7.76E-02 | |
| Cytokine signaling | IL-17A signaling in airway cells | 72 | 21 | 1.35E-02 | 2 | 8.51E-02 | 11 | 1.58E-01 |
| Prolactin signaling | 80 | 22 | 3.72E-02 | 22 | 1.45E-02 | 17 | 6.46E-03 | |
| Cancer | Glioma signaling | 112 | 29 | 1.55E-02 | 27 | 1.62E-02 | 19 | 2.14E-02 |
| p53 signaling | 96 | 32 | 1.48E-03 | 27 | 1.23E-02 | 20 | 8.51E-03 | |
| Small cell lung cancer signaling | 89 | 27 | 6.03E-04 | 26 | 3.63E-04 | 20 | 2.57E-04 | |
| Cellular growth, proliferation and development | Cleavage and polyadenylation of pre-mRNA | 12 | 5 | 8.32E-02 | 5 | 6.03E-02 | 4 | 5.01E-02 |
| EGF signaling | 62 | 21 | 2.88E-03 | 20 | 2.34E-03 | 13 | 1.66E-02 | |
| FAK signaling | 101 | 27 | 1.32E-02 | 26 | 9.33E-03 | 17 | 3.47E-02 | |
| JAK/Stat signaling | 70 | 26 | 5.37E-04 | 24 | 8.71E-04 | 20 | 1.07E-04 | |
| Oncostatin M signaling | 35 | 12 | 3.55E-02 | 11 | 4.47E-02 | 8 | 5.01E-02 | |
| PDGF signaling | 85 | 25 | 1.07E-02 | 24 | 6.92E-03 | 18 | 5.01E-03 | |
| Thrombopoietin signaling | 63 | 17 | 4.90E-02 | 17 | 2.29E-02 | 12 | 3.31E-02 | |
| VEGF signaling | 103 | 25 | 7.59E-02 | 25 | 3.47E-02 | 16 | 9.55E-02 | |
| Cell cycle regulation | Cyclins and cell cycle regulation | 89 | 24 | 2.75E-02 | 23 | 2.19E-02 | 13 | 1.80E-01 |
| GADD45 signaling | 22 | 9 | 8.51E-03 | 8 | 2.40E-02 | 4 | 2.26E-01 | |
| Mitotic roles of polo-like kinase | 70 | 18 | 1.39E-01 | 18 | 7.24E-02 | 9 | 4.44E-01 | |
| Growth Ffactor signaling | ErbB2-ErbB3 signaling | 60 | 19 | 1.82E-02 | 19 | 7.08E-03 | 15 | 3.02E-03 |
| Apoptosis | April mediated signaling | 43 | 13 | 3.72E-02 | 11 | 9.12E-02 | 6 | 3.24E-01 |
| Aryl hydrocarbon receptor signaling | 161 | 40 | 1.48E-02 | 34 | 6.92E-02 | 21 | 1.96E-01 | |
| Myc mediated apoptosis signaling | 60 | 20 | 1.05E-02 | 19 | 8.71E-03 | 14 | 9.33E-03 | |
| Cellular stress and injury | Endoplasmic reticulum stress pathway | 18 | 7 | 6.03E-02 | 7 | 3.98E-02 | 4 | 1.73E-01 |
| Disease-specific pathways | Parkinson’s signaling | 16 | 4 | 4.32E-01 | 4 | 3.61E-01 | - | - |
| Neurotransmitters and other nervous system signaling | Cholecystokinin/gastrin-mediated signaling | 106 | 24 | 2.59E-01 | 20 | 4.56E-01 | - | - |
bold: with statistical significance.